BRPI0514364A - formulação de fotossensibilizante de baixa concentração e método de terapia de baixa concentração para o tratamento pdt de doença - Google Patents

formulação de fotossensibilizante de baixa concentração e método de terapia de baixa concentração para o tratamento pdt de doença

Info

Publication number
BRPI0514364A
BRPI0514364A BRPI0514364-0A BRPI0514364A BRPI0514364A BR PI0514364 A BRPI0514364 A BR PI0514364A BR PI0514364 A BRPI0514364 A BR PI0514364A BR PI0514364 A BRPI0514364 A BR PI0514364A
Authority
BR
Brazil
Prior art keywords
low concentration
pdt
formulation
photosensitizer
tissue
Prior art date
Application number
BRPI0514364-0A
Other languages
English (en)
Inventor
Nifantiev Nikolay
Albrecht Volker
Original Assignee
Ceramoptec Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramoptec Ind Inc filed Critical Ceramoptec Ind Inc
Publication of BRPI0514364A publication Critical patent/BRPI0514364A/pt
Publication of BRPI0514364B1 publication Critical patent/BRPI0514364B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulação de Fotossensibilizante de Baixa Concentração e Método de Terapia de Baixa Concentração para o Tratamento PDT de Doença. Uma formulação de baixa concentração para fotossensibilizantes hidrofóbicos (PS) e método aperfeiçoado de terapia fotodinâmica ("PDT"). Foi constatado que tratamentos de PDT que usam as formulações de baixa concentração descritas proporcionam dosagens mais precisas, mais eficientes e mais convenientes. Foi verificado que a formulação inventiva (1) reduz o tempo para que se acumule um nível terapeuticamente efetivo de fotossensibilizante no tecido doente e (2) reduz o tempo para alcançar uma relação suficiente de fotossensibilizante no tecido doente versus tecido saudável. Como resultado, a formulação da invenção reduz o intervalo de tempo entre a aplicação PS /administração e irradiação (o intervalo de droga-luz ou "DLI") e pode proporcionar uma opção de tratamento Foi no mesmo dia". A formulação inventiva pode ser usada para regimes de tratamento PDT em que são administrados fotossensibilizantes em pelo menos uma dose pré-selecionada, incluindo uma terapia de baixa concentração para PDT. Em particular, quando o fotossensibilizante é meta Tetra-Hidroxi-Fenil Clorina (m-THPC), então uma concentração de 0,8 mg/ml a 0,04 mg/ml numa mistura de propilenoglicol e etanol puros numa relação de volume de 3:2 acumula-se no tecido doente e diferencia suficientemente rápido entre o tecido doente e o tecido normal para tornar possíveis a administração de tratamento de ativação.
BRPI0514364-0A 2004-08-16 2005-07-22 Formulação de fotossensibilizante de baixa concentração e método de terapia de baixa concentração para o tratamento pdt de doença BRPI0514364B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60226404P 2004-08-16 2004-08-16
US60/602,264 2004-08-16
US11/153,703 2005-06-15
US11/153,703 US7825153B2 (en) 2004-08-16 2005-06-15 Photosensitizer formulations and their use
PCT/US2005/026051 WO2006023194A2 (en) 2004-08-16 2005-07-22 Improved photosensitizer formulations and their use

Publications (2)

Publication Number Publication Date
BRPI0514364A true BRPI0514364A (pt) 2008-06-10
BRPI0514364B1 BRPI0514364B1 (pt) 2021-06-22

Family

ID=35800792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514364-0A BRPI0514364B1 (pt) 2004-08-16 2005-07-22 Formulação de fotossensibilizante de baixa concentração e método de terapia de baixa concentração para o tratamento pdt de doença

Country Status (18)

Country Link
US (2) US7825153B2 (pt)
EP (1) EP1786431B1 (pt)
JP (1) JP5612246B2 (pt)
KR (2) KR101158192B1 (pt)
CN (1) CN101056642B (pt)
AU (2) AU2005277790B2 (pt)
BR (1) BRPI0514364B1 (pt)
CA (1) CA2577441C (pt)
DK (1) DK1786431T3 (pt)
ES (1) ES2552033T3 (pt)
HU (1) HUE026361T2 (pt)
IL (1) IL181300A (pt)
MX (2) MX2007001902A (pt)
PL (1) PL1786431T3 (pt)
PT (1) PT1786431E (pt)
RU (1) RU2371181C2 (pt)
SI (1) SI1786431T1 (pt)
WO (1) WO2006023194A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10311027A1 (de) * 2003-03-13 2004-09-30 Siemens Ag Mess- und Simulationssystem für Werkzeug- oder Produktionsmaschinen
US20070031482A1 (en) * 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US20080275432A1 (en) * 2006-05-11 2008-11-06 Ceramoptec Industries, Inc. Photodynamic foam composition and sclerosis treatment
US8180444B2 (en) * 2007-06-22 2012-05-15 Biolitec Pharma Marketing Ltd Enhanced PhotoDynamic Therapy with immune system assist
US20100256125A1 (en) * 2009-04-06 2010-10-07 Zila Pharmaceuticals, Inc. Use of improved toluidine blue in photodynamic therapy
WO2010129775A1 (en) 2009-05-06 2010-11-11 University Of Virginia Patent Foundation Self-illuminated handheld lens for retinal examination and photography and related method thereof
RU2521327C1 (ru) * 2012-12-12 2014-06-27 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России) Препарат для фотодинамической терапии и способ фотодинамической терапии рака с его использованием

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017501A (en) * 1975-10-24 1977-04-12 American Cyanamid Company Process for preparing pyridinium chloride salts of alkyl esters of 2-chloro-N-2-hydroxyethylacetamide
ZA855561B (en) * 1984-07-27 1986-03-26 Univ Illinois Photodynamic herbicides
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5162519A (en) * 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
US4999375A (en) * 1989-04-11 1991-03-12 Hoffmann-La Roche Inc. Psoralen reagent compositions for extracorporeal treatment of blood
US5173504A (en) * 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
ES2096664T3 (es) * 1990-10-12 1997-03-16 Raychem Ltd Instalacion para proteccion de circuitos.
US5492924A (en) * 1993-09-24 1996-02-20 Fox Chase Cancer Center Phorbine derivatives and their use in the diagnosis and therapy of cancer
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
US5616342A (en) * 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
RU2066552C1 (ru) * 1996-02-12 1996-09-20 Товарищество с ограниченной ответственностью "Био Прогресс" Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
CA2298526A1 (en) * 1997-07-28 1999-02-04 Dermatolazer Technologies Ltd Phototherapy based method for treating pathogens and composition for effecting same
US6609014B1 (en) * 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
WO2001060360A1 (en) * 2000-02-17 2001-08-23 Meiji Seika Kaisha Ltd. Photodynamic therapy for selectively closing neovasa in eyeground tissue
US6462192B2 (en) * 2001-01-23 2002-10-08 Miravant Pharmaceuticals, Inc. Processes for large scale production of tetrapyrroles
US8106038B2 (en) 2001-02-15 2012-01-31 Qlt Inc. Method for reducing or preventing PDT related inflammation
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
ATE336497T1 (de) * 2001-06-01 2006-09-15 Ceramoptec Gmbh Wasserlösliche porphyrinderivate für die photodynamische therapie, deren verwendung und herstellung
EP1277470A1 (fr) * 2001-07-17 2003-01-22 Steba Biotech N.V. Formulation galénique injectable pour utilisation dans un diagnostic ou une thérapie photodynamique et son procédé de préparation
EP1279676A1 (en) * 2001-07-19 2003-01-29 Institut Curie Porphyrin derivatives for photodynamic therapy
US7115617B2 (en) * 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
BR0214009A (pt) 2001-11-09 2004-11-03 Quadra Logic Tech Inc Método e composição para estimular o crescimento de pelos sobre a pele
US20030167033A1 (en) 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
US6949581B2 (en) * 2003-03-21 2005-09-27 Ceramoptec Industries, Inc. Water-soluble mono-PEGylated tetrapyrrole derivatives for photodynamic therapy and method of production

Also Published As

Publication number Publication date
KR101074941B1 (ko) 2011-10-18
EP1786431A2 (en) 2007-05-23
IL181300A (en) 2016-04-21
MX2007001902A (es) 2007-04-25
CN101056642A (zh) 2007-10-17
JP2008509998A (ja) 2008-04-03
RU2007109602A (ru) 2008-09-27
WO2006023194A2 (en) 2006-03-02
AU2009243407B2 (en) 2011-04-28
PL1786431T3 (pl) 2016-04-29
SI1786431T1 (sl) 2016-01-29
KR101158192B1 (ko) 2012-06-20
CA2577441E (en) 2006-03-02
EP1786431B1 (en) 2015-10-28
CN101056642B (zh) 2011-08-17
AU2005277790A1 (en) 2006-03-02
ES2552033T3 (es) 2015-11-25
US7825153B2 (en) 2010-11-02
MX336390B (es) 2016-01-18
AU2005277790B2 (en) 2009-09-03
IL181300A0 (en) 2008-04-13
AU2009243407A1 (en) 2009-12-17
KR20100040957A (ko) 2010-04-21
BRPI0514364B1 (pt) 2021-06-22
JP5612246B2 (ja) 2014-10-22
US20060035952A1 (en) 2006-02-16
HUE026361T2 (en) 2016-06-28
KR20070048738A (ko) 2007-05-09
CA2577441A1 (en) 2006-03-02
PT1786431E (pt) 2016-01-06
CA2577441C (en) 2010-09-28
RU2371181C2 (ru) 2009-10-27
WO2006023194A3 (en) 2006-06-15
US8580839B2 (en) 2013-11-12
US20080195032A1 (en) 2008-08-14
DK1786431T3 (en) 2016-01-25
EP1786431A4 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
Kasche et al. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid
Allison et al. Clinical PD/PDT in North America: an historical review
Gold et al. 5‐aminolevulinic acid photodynamic therapy: where we have been and where we are going
Dahlman et al. Laser photoradiation therapy of cancer
Calzavara-Pinton et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
Calzavara-Pinton et al. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis
Qiang et al. Photodynamic therapy for malignant and non-malignant diseases: clinical investigation and application
MX336390B (es) Formulaciones fotosensibilizadoras mejoradas y su uso.
Ammann et al. Topical photodynamic therapy in verrucae: a pilot study
Baas et al. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study
Buggiani et al. Photodynamic therapy: off-label and alternative use in dermatological practice
Oseroff Photodynamic therapy
Ziolkowski et al. Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture.
RU2336917C1 (ru) Способ лечения больных псориазом
Ledo et al. Phototherapy, photochemotherapy, and photodynamic therapy: unapproved uses or indications
Rai et al. Phototherapy: an Indian perceptive
LOWE Optimizing therapy: tazarotene in combination with phototherapy
Levy et al. Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A
Harvey et al. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398
US8318794B2 (en) Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins
Silva et al. Time‐dependent photodynamic damage to blood vessels: correlation with serum photosensitizer levels
Gomez et al. 8-MOP bath PUVA in the treatment of psoriasis: clinical results in 42 patients
RU2336078C2 (ru) Применение веществ синтеза порфиринов для применения в фототерапии, а также для лечения заболеваний кожи и/или суставов
Stables et al. Photodynamic therapy in dermatology

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOLITEC PHARMA MARKETING LTD. (MY)

B25A Requested transfer of rights approved

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.